Inhaled corticosteroids for stable chronic obstructive pulmonary disease
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The role of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) has been the subject of much controversy. Major international guidelines recommend selective use of ICS. Recently published meta-analyses have reported conflicting findings on the effects of inhaled steroid therapy in COPD. OBJECTIVES: The objective of the review is to determine the efficacy of regular use of inhaled corticosteroids in patients with stable COPD. SEARCH STRATEGY: A pre-defined search strategy was used to search the Cochrane Airways Group specialised register for relevant literature. Searches are current as of October 2006. SELECTION CRITERIA: We selected randomised trials comparing any dose of any type of inhaled steroid with a placebo control in patients with COPD. Acute bronchodilator reversibility to short term beta2-agonists and bronchial hyperresponsiveness were not exclusion criteria. The a priori primary outcome was change in lung function. Data on mortality, exacerbations, quality of life and symptoms, rescue bronchodilator use, exercise capacity, biomarkers and safety were also analysed. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and extracted data. Study authors were contacted for additional information. Adverse effects information was collected from the trials. MAIN RESULTS: Forty-seven primary studies with 13,139 participants met the inclusion criteria. Medium term use of ICS (> two months and up to six months) resulted in a small improvement in FEV1 in some studies. Long term use of ICS (> six months) did not significantly reduce the rate of decline in FEV1 in COPD patients (weighted mean difference (WMD) 5.80 ml/year with ICS over placebo, 95% CI -0.28 to 11.88, 2333 participants). There was no statistically significant effect on mortality in COPD patients (OR 0.98, 95% CI 0.83 to 1.16, 8390 participants). Long term use of ICS reduced the mean rate of exacerbations in those studies where pooling of data was possible (WMD -0.26 exacerbations per patient per year, 95% CI -0.37 to -0.14, 2586 participants). ICS slowed the rate of decline in quality of life, as measured by the St George's Respiratory Questionnaire (WMD -1.22 units/year, 95% CI -1.83 to -0.60, 2507 participants). Response to ICS was not predicted by oral steroid response, bronchodilator reversibility or bronchial hyper-responsiveness in COPD patients. There was an increased risk of oropharyngeal candidiasis (OR 2.49, 95% CI 1.78 to 3.49, 4380 participants) and hoarseness. The few long term studies that measured bone effects generally showed no major effect on fractures and bone mineral density over 3 years. AUTHORS' CONCLUSIONS: Patients and clinicians should balance the potential benefits of inhaled steroids in COPD (reduced rate of exacerbations, reduced rate of decline in quality of life), against the known increase in local side effects (oropharyngeal candidiasis and hoarseness). The risk of long term adverse effects is unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interpreting thresholds for a clinically significant change in health status in asthma and COPD
Jones, P. W. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00063702 · Cited by 585
Cited by
Glucocorticoid resistance in inflammatory diseases
Barnes, P. J., & Adcock, I. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60326-3 · Cited by 983
Self-management education for patients with chronic obstructive pulmonary disease
Effing, T., Monninkhof, E. E., van der Valk, P. P. D. L. P. M., Zielhuis, G. G., Walters, E. H., van der Palen, J. J., & Zwerink, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002990.pub2 · Cited by 536
Glucocorticosteroids: current and future directions
Barnes, P. J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01199.x · Cited by 533
Leucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451
Molecular and cellular mechanisms of pulmonary fibrosis
Todd, N. W., Luzina, I. G., & Atamas, S. P. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-11 · Cited by 418
Medication adherence issues in patients treated for COPD
Restrepo, R. (2008) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s3036 · Cited by 407
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Kew, K. M., & Seniukovich, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010115.pub2 · Cited by 398
Role of HDAC2 in the Pathophysiology of COPD
Barnes, P. J. (2009) · Annual Review of Physiology · doi:10.1146/annurev.physiol.010908.163257 · Cited by 318
Barnes, P. J. (2010) · Pharmaceuticals · doi:10.3390/ph3030514 · Cited by 277
Nannini, L. J., Poole, P., Milan, S. J., Holmes, R., & Normansell, R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003794.pub4 · Cited by 274
Loke, Y. K., Cavallazzi, R., & Singh, S. (2011) · Thorax · doi:10.1136/thx.2011.160028 · Cited by 267
Nannini, L. J., Lasserson, T. J., & Poole, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006829.pub2 · Cited by 264
Self-citation
Metadata
- Authors
- Yang, I. A., Fong, K., Sim, E. H. A., Black, P. N., & Lasserson, T. J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2007-04-18
- Issue
- 2
- Pages
- CD002991-CD002991
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2069931082
- Cited by
- 153
- References
- 1
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.